{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:14:24Z","timestamp":1789010064710,"version":"build-2803163510"},"reference-count":28,"publisher":"Japan Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2009]]},"DOI":"10.1507\/endocrj.k08e-186","type":"journal-article","created":{"date-parts":[[2009,7,30]],"date-time":"2009-07-30T05:59:26Z","timestamp":1248933566000},"page":"579-584","source":"Crossref","is-referenced-by-count":63,"title":["Differential Expression of Somatostatin and Dopamine Receptor Subtype Genes in Adrenocorticotropin (ACTH)-secreting Pituitary Tumors and Silent Corticotroph Adenomas"],"prefix":"10.1507","volume":"56","author":[{"given":"Toru","family":"TATENO","sequence":"first","affiliation":[{"name":"Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental University Graduate School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"KATO","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental University Graduate School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"TANI","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental University Graduate School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"OYAMA","sequence":"additional","affiliation":[{"name":"Departments of Hypothalamic and Pituitary Surgery, Toranomon Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shozo","family":"YAMADA","sequence":"additional","affiliation":[{"name":"Departments of Hypothalamic and Pituitary Surgery, Toranomon Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"HIRATA","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental University Graduate School"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199503233321207"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tateno T, Izumiyama H, Doi M, Yoshimoto T, Shichiri M, Inoshita N, Oyama K, Yamada S, Hirata Y (2007) Differential gene expression in ACTH -secreting and non-functioning pituitary tumors. <I>Eur J Endocrinol <\/I>157:717-724","DOI":"10.1530\/EJE-07-0428"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lamberts SW, Oosterom R, Neufeld M, del Pozo E (1985) The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. <I>J Clin Endocrinol Metab <\/I>60:1161-1165","DOI":"10.1210\/jcem-60-6-1161"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.6.2779"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2001-012012"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.53.125"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kennedy AL, Sheridan B, Montgomery DA (1978) ACTH and cortisol response to bromocriptine, and results of long-term therapy, in Cushing&rsquo;s disease. <I>Acta Endocrinol (Copenh) <\/I>89:461-468","DOI":"10.1530\/acta.0.0890461"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Boscaro M, Benato M, Mantero F (1983) Effect of bromocriptine in pituitary-dependent Cushing&rsquo;s syndrome. <I>Clin Endocrinol (Oxf) <\/I>19:485-491","DOI":"10.1111\/j.1365-2265.1983.tb00023.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC , Marcondes JB, Chimelli LM, Fontes R, Niemeyer P, de Carvalho DP, Kineman RD, Gadelha MR (2008) Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. <I>Eur J Endocrinol <\/I>158:295-303","DOI":"10.1530\/EJE-07-0562"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.6.2003"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.6.2315"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Taylor JE , Culler MD, Cavazzini L, degli Uberti EC (2004) Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. <I>J Clin Endocrinol Metab <\/I>89:5181-5188","DOI":"10.1210\/jc.2003-031954"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2005.05.061"},{"key":"14","unstructured":"14. Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W, Lamberts SW (2005) Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. <I>J Endocrinol Invest <\/I>28:36-42"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1245"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW (2005) The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. <I>Eur J Endocrinol <\/I>152:645-654","DOI":"10.1530\/eje.1.01876"},{"issue":"2","key":"17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/eje.0.1300125","volume":"130","year":"1994","ISSN":"https:\/\/id.crossref.org\/issn\/0804-4643","issn-type":"print"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Cervia D, Nunn C, Fehlmann D, Langenegger D, Schuepbach E, Hoyer D (2003) Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs. <I>Br J Pharmaco<\/I>l 139:109-121","DOI":"10.1038\/sj.bjp.0705235"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M501998200"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ (2005) Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. <I>Am J Physiol Endocrinol Metab <\/I>289:E278-E287","DOI":"10.1152\/ajpendo.00004.2005"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Silva AP, Schoeffter P, Weckbecker G, Bruns C, Schmid HA (2005) Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. <I>Eur J Endocrinol <\/I>153:R7-R10","DOI":"10.1530\/eje.1.01998"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.4.1386"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Park S, Kamegai J, Kineman RD (2003) Role of glucocorticoids in the regulation of pituitary somatostatin receptor subtype (sst1-sst5) mRNA levels: evidence for direct and somatostatin-mediated effects. <I>Neuroendocrinology <\/I>78:163-175","DOI":"10.1159\/000072798"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Lamberts SW, Klijn JG, de Quijada M, Timmermans HA, Uitterlinden P, de Jong FH, Birkenhager JC (1980) The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing&rsquo;s disease and Nelson&rsquo;s syndrome. <I>J Clin Endocrinol Metab <\/I>51:307-311","DOI":"10.1210\/jcem-51-2-307"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW (2004) Dopamine receptor expression and function in corticotroph pituitary tumors. <I>J Clin Endocrinol Metab <\/I>89:2452-2462","DOI":"10.1210\/jc.2003-030837"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1210\/er.14.4.443"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Invitti C, De Martin M, Danesi L, Cavagnini F (1995) Effect of injectable bromocriptine in patients with Cushing&rsquo;s disease. <I>Exp Clin Endocrinol Diabetes <\/I>103:266-271","DOI":"10.1055\/s-0029-1211361"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1210\/er.13.2.220"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/endocrj\/56\/4\/56_K08E-186\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:49:34Z","timestamp":1618296574000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/endocrj\/56\/4\/56_K08E-186\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.k08e-186","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009]]}}}